CR20190096A - Análogos de insulina - Google Patents

Análogos de insulina

Info

Publication number
CR20190096A
CR20190096A CR20190096A CR20190096A CR20190096A CR 20190096 A CR20190096 A CR 20190096A CR 20190096 A CR20190096 A CR 20190096A CR 20190096 A CR20190096 A CR 20190096A CR 20190096 A CR20190096 A CR 20190096A
Authority
CR
Costa Rica
Prior art keywords
insulin
present
insulin analogues
relates
methods
Prior art date
Application number
CR20190096A
Other languages
English (en)
Inventor
Michael Colin Lawrence
Danny Hung Chieh Chou
Oliviera M Baldomero
John Gerbrant Tasman Menting
Brian Smith
Helena Safavi-Hemami
Original Assignee
Walter & Eliza Hall Inst Medical Res
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016902883A external-priority patent/AU2016902883A0/en
Application filed by Walter & Eliza Hall Inst Medical Res, Univ Utah Res Found filed Critical Walter & Eliza Hall Inst Medical Res
Priority claimed from PCT/AU2017/050758 external-priority patent/WO2018014091A1/en
Publication of CR20190096A publication Critical patent/CR20190096A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Metallurgy (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)

Abstract

La presente invención se refiere particularmente a análogos de insulina que tienen cadenas B cortas. La presente invención también se refiere a la estructura cristal de insulina del veneno de caracoles cono y a métodos para utilizar el cristal, así como información estructural relacionada para cribar y diseñar análogos de insulina que interactúen o modelen el receptor de insulina. La presente invención también se refiere a métodos terapéuticos y profilácticos utilizando análogos de insulina.
CR20190096A 2016-07-22 2017-07-21 Análogos de insulina CR20190096A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016902883A AU2016902883A0 (en) 2016-07-22 Insulin Analogs
US201762483118P 2017-04-07 2017-04-07
PCT/AU2017/050758 WO2018014091A1 (en) 2016-07-22 2017-07-21 Insulin analogs

Publications (1)

Publication Number Publication Date
CR20190096A true CR20190096A (es) 2019-09-16

Family

ID=65524551

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190096A CR20190096A (es) 2016-07-22 2017-07-21 Análogos de insulina

Country Status (15)

Country Link
US (2) US11248034B2 (es)
EP (1) EP3487876A4 (es)
JP (2) JP7143275B2 (es)
KR (2) KR20230070049A (es)
CN (2) CN116874584A (es)
AU (1) AU2021269301B2 (es)
BR (1) BR112019000991A2 (es)
CL (1) CL2019000159A1 (es)
CR (1) CR20190096A (es)
IL (1) IL264330B2 (es)
MA (1) MA45727A (es)
MX (1) MX2019000829A (es)
RU (1) RU2769476C2 (es)
SG (1) SG11201900181RA (es)
ZA (1) ZA201901095B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034701A1 (en) * 2016-08-30 2018-03-08 Board Of Regents, The University Of Texas System Production of seleno-biologics in genomically recoded organisms
WO2023229624A1 (en) * 2022-05-26 2023-11-30 Transdermal Delivery Solutions Corp. (D.B.A. Hypospray Pharma) Transdermal insulin formulations and methods of use thereof
WO2023234709A1 (ko) 2022-05-31 2023-12-07 주식회사 엘지에너지솔루션 고분자 고체 전해질 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104305C1 (ru) * 1986-08-29 1998-02-10 Ново Нордиск А.С. Аналоги инсулина человека, способ их получения, раствор для инъекций
WO2005095443A1 (ja) * 2004-03-31 2005-10-13 Cardio Incorporated ペプチド改変を利用したドラッグデリバリーシステム
HUE029512T2 (en) * 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
US7790677B2 (en) * 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
ES2558930T3 (es) * 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
US9200053B2 (en) * 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
CA2732439A1 (en) * 2008-07-31 2010-02-04 Case Western Reserve University Halogen-stabilized insulin
CN102245633A (zh) * 2008-12-09 2011-11-16 诺沃—诺迪斯克有限公司 新的胰岛素类似物
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
EP2720713A2 (en) * 2011-06-17 2014-04-23 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
RU2678134C2 (ru) * 2013-03-14 2019-01-23 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты инсулин-инкретин
JP2016516728A (ja) 2013-03-15 2016-06-09 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 第２部位インスリン類似体
EP3008081B1 (en) * 2013-06-14 2017-08-30 President and Fellows of Harvard College Stabilized polypeptide insulin receptor modulators
WO2018014091A1 (en) 2016-07-22 2018-01-25 University Of Utah Research Foundation Insulin analogs
EP4048686A4 (en) * 2019-10-24 2024-01-03 University Of Utah Research Foundation NEW MINI INSULIN WITH EXTENDED C-TERMINAL A-CHAIN

Also Published As

Publication number Publication date
BR112019000991A2 (pt) 2019-07-02
MX2019000829A (es) 2019-08-29
KR20230070049A (ko) 2023-05-19
NZ750355A (en) 2023-10-27
JP2019534843A (ja) 2019-12-05
SG11201900181RA (en) 2019-02-27
AU2021269301A1 (en) 2021-12-09
JP2022191233A (ja) 2022-12-27
JP7143275B2 (ja) 2022-09-28
KR20190039719A (ko) 2019-04-15
US11248034B2 (en) 2022-02-15
IL264330B1 (en) 2024-01-01
US20190241640A1 (en) 2019-08-08
RU2769476C2 (ru) 2022-04-01
RU2019100497A3 (es) 2021-05-11
CN116874584A (zh) 2023-10-13
AU2021269301B2 (en) 2023-12-21
CN110072884A (zh) 2019-07-30
CL2019000159A1 (es) 2019-08-16
CN110072884B (zh) 2023-07-28
IL264330A (es) 2019-03-31
US20220340636A1 (en) 2022-10-27
RU2019100497A (ru) 2020-08-24
IL264330B2 (en) 2024-05-01
MA45727A (fr) 2019-05-29
ZA201901095B (en) 2022-04-28
EP3487876A4 (en) 2020-02-19
KR102529353B1 (ko) 2023-05-04
EP3487876A1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
CY1121750T1 (el) Cot διαμορφωτες και μεθοδοι χρησης αυτων
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
ECSP16073171A (es) Ciclopropilaminas como inhibidores de lsd1
DOP2017000046A (es) Anticuerpos anti tigit
CL2016000908A1 (es) Métodos para el tratamiento de afecciones asociados a la activación del complemento dependiente de masp-2 declaración relacionada con el listado de secuencias
BR112016028891A2 (pt) processos de trens de sementes e usos dos mesmos
UY36068A (es) INHIBIDORES DE TGF-ß Y MÉTODOS DE USO
EA201691911A1 (ru) Быстродействующие композиции инсулина
GT201300319A (es) Coagonistas del receptor de glucagón / glp-1
UY36870A (es) Análogos de insulina novedosos
BR112016000903A2 (pt) anticorpos
UY35174A (es) Nuevos moduladores del receptor huerfano gamma relacionado con retinoides
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
BR112018002461A2 (pt) compostos para dispositivos opticamente ativos
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
EA201691754A1 (ru) Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение
CR20170231A (es) Anticuerpos mejorados contra il-6
ECSP16075416A (es) Anticuerpos de il-21
CR20190096A (es) Análogos de insulina
DOP2016000311A (es) Nuevos compuestos
CR20160448A (es) Nuevos derivados de piridina
DOP2016000064A (es) Derivados de fenilalanina sustituidos
CR20140473A (es) Compuestos de pirazol como inhibidores de sglt1
BR112016019389A2 (pt) vacina, e, peptídeo
ECSP16074207A (es) Pirazinas moduladoras de gpr6